PS
NVAX icon

Principal Securities’s Novavax NVAX Stock Holding History

Principal Securities’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$121 – 3825
2025
Q1 		$121 Hold
15
– – ﹤0.01% 3498
2024
Q4 		$121 Buy
+15
New +$145 ﹤0.01% 3493
2024
Q2 		– Sell
-200
Closed -$956 – 3451
2024
Q1 		$956 Hold
200
– – ﹤0.01% 3051
2023
Q4 		$960 Buy
+200
New +$1.22K ﹤0.01% 2966

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Principal Securities's NVAX Position: Q2 2025 in Review

Principal Securities sold out of Novavax (NVAX) in Q2 2025, closing a stake of 15 shares — an estimated $121 sold.

Principal Securities first reported a position in NVAX in Q4 2023 and held it in 4 quarters. The position peaked at $960 in Q4 2023. 250 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

  • Principal Securities reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
  • Principal Securities sold 15 Novavax shares in Q2 2025, an estimated $121.
  • Principal Securities first reported a position in Novavax in Q4 2023 and held it in 4 quarters.
  • Principal Securities's Novavax position peaked at $960 in Q4 2023.
  • 250 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Principal Securities's 13F filing for Q2 2025, filed 11 Aug 2025.